P/E at 26.24 vs Industry's 34.53: What the Data Shows for Dr Reddys Laboratories Ltd

Valuation Picture: Discount Amidst Sector Premiums

The current P/E of 26.24 for Dr Reddys Laboratories Ltd stands in contrast to the industry’s average of 34.53, indicating the stock is trading at a substantial discount to its sector. This valuation gap suggests that investors are pricing in either a more cautious outlook on the company’s near-term earnings growth or a premium being accorded to other sector constituents. The discount may also reflect concerns over competitive pressures or regulatory challenges within the pharmaceutical space. Dr Reddys Laboratories Ltd’s market capitalisation of ₹1,09,840.86 crores places it firmly in the large-cap category, yet the valuation gap invites questions about relative earnings quality and growth prospects — previously rated Buy, what is Dr Reddys Laboratories Ltd’s current rating?

Performance Across Timeframes: Mixed Momentum

Examining the stock’s returns reveals a divergence between short- and medium-term performance. Over the past year, Dr Reddys Laboratories Ltd has delivered a positive return of 7.52%, outperforming the Sensex’s decline of 6.88%. This outperformance extends to the three-month horizon, where the stock gained 2.79% compared to the Sensex’s 8.98% fall. The one-month return is even more robust at 8.13%, while the year-to-date gain stands at 3.54%, again ahead of the Sensex’s negative 11.55%. However, the one-week and one-day performances show slight underperformance, with the stock down 1.57% and 0.18% respectively, while the Sensex posted gains in these periods. This suggests some recent profit-taking or short-term volatility — is this a temporary pause or a sign of weakening momentum?

Moving Average Configuration: Technical Signals

The technical setup for Dr Reddys Laboratories Ltd offers further insight into its price dynamics. The stock currently trades above its 20-day, 50-day, 100-day, and 200-day moving averages, indicating a sustained medium- to long-term uptrend. However, it remains below its 5-day moving average, signalling some short-term resistance or consolidation. This configuration often points to a recent pullback within an overall positive trend, suggesting that the stock may be undergoing a minor correction or a pause before potentially resuming its upward trajectory. The fact that it is just 4.51% away from its 52-week high reinforces the notion of relative strength over the past year. The 5-day moving average resistance raises the question — is this a genuine recovery or a dead-cat bounce?

Sector Context: Pharmaceuticals & Biotechnology Performance

The Pharmaceuticals & Biotechnology sector has seen a generally positive earnings season, with 19 stocks having declared results so far. Of these, 13 reported positive outcomes, 4 were flat, and only 2 posted negative results. This broadly favourable sector backdrop contrasts with the valuation discount seen in Dr Reddys Laboratories Ltd, suggesting that the company’s relative valuation may be influenced by company-specific factors rather than sector-wide trends. The sector’s resilience is reflected in the stock’s outperformance over the past year and three months, but the recent short-term underperformance invites scrutiny — should investors in Dr Reddys Laboratories Ltd hold, buy more, or reconsider?

Rating Context: Previous Mojo Grade and Reassessment

Dr Reddys Laboratories Ltd was previously rated Buy by MarketsMOJO, with a Mojo Score of 58.0. On 4 May 2026, the rating was updated to Hold, reflecting changes in the underlying data and valuation metrics. This reassessment aligns with the stock’s current valuation discount to the sector and the mixed signals from recent price performance and technical indicators. The rating change underscores the importance of balancing valuation against momentum and sector dynamics — what is the current rating for Dr Reddys Laboratories Ltd?

Longer-Term Performance: A Mixed Legacy

Looking beyond the recent year, Dr Reddys Laboratories Ltd has delivered a 47.67% return over three years, more than double the Sensex’s 21.65% gain in the same period. However, the five-year return of 26.13% trails the Sensex’s 49.15%, and the ten-year return of 116.80% is also below the Sensex’s 197.93%. This suggests that while the company has outperformed in the medium term, its longer-term growth has lagged broader market gains. The stock’s ability to sustain momentum in the face of sector and market cycles remains a key consideration for investors.

Conclusion: What the Data Collectively Shows

The data on Dr Reddys Laboratories Ltd paints a picture of a large-cap pharmaceutical stock trading at a meaningful valuation discount to its sector peers, despite a solid one-year and medium-term performance record. The mixed short-term price action and technical signals suggest some caution, while the sector’s generally positive earnings environment contrasts with the stock’s relative valuation. The recent rating reassessment from Buy to Hold by MarketsMOJO reflects these complexities. Investors may find value in analysing whether the current valuation gap represents an opportunity or a reflection of underlying challenges — should investors hold, buy more, or reconsider their position in Dr Reddys Laboratories Ltd?

53% Discount is LIVE - Get MojoOne + Stock of the Week for 3 Years Start Today